SCHEDULE 13G: Woodline Partners Discloses 6.8% Stake in Tenaya Therapeutics
Beneficial Ownership Report
Woodline Partners LP has filed a Schedule 13G, revealing a beneficial ownership of 6.8% in Tenaya Therapeutics, Inc.'s common stock as of March 31, 2025.
Summary
- Woodline Partners LP, a Delaware limited partnership and investment adviser to Woodline Master Fund LP, has reported beneficial ownership of 5,916,167 shares of Tenaya Therapeutics, Inc. common stock.
- This ownership represents 6.8% of Tenaya Therapeutics' outstanding common stock.
- The percentage is calculated based on 87,582,646 shares of common stock outstanding as of March 4, 2025, as reported in the Company's Annual Report on Form 10-K filed March 10, 2025.
- Woodline Partners LP holds shared voting power and shared dispositive power over all 5,916,167 shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Tenaya Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook. It is a neutral regulatory filing.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing is a standard regulatory disclosure required when an institutional investor acquires beneficial ownership of more than 5% of a company's outstanding shares. It indicates a significant stake by Woodline Partners LP in Tenaya Therapeutics, a biotechnology company.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor's stake may be viewed positively by other investors, potentially signaling confidence in the company's prospects or increasing liquidity.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date as of which Tenaya Therapeutics, Inc. reported 87,582,646 shares of Common Stock outstanding in its Annual Report on Form 10-K. |
| 03/10/2025 | Date Tenaya Therapeutics, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the SEC. |
| 03/31/2025 | Date of event which requires the filing of this Schedule 13G statement. |
| 05/15/2025 | Date the Schedule 13G statement was signed and filed by Woodline Partners LP. |
Keywords
Tenaya Therapeutics, Woodline Partners LP, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.